Patient-reported outcomes (PROs) in the double-blind phase 3 trial (NGR015) with NGR-hTNF plus best investigator choice (BIC) versus placebo plus BIC for previously treated patients with malignant pleural mesothelioma (MPM)
Gregorc, Vanesa, Bulotta, Alessandra, Viganò, Maria G, Citterio, Giovanni, Petrella, Giovanna, Brioschi, Elena, Ducceschi, Monika, Gianni, Luca, Colombi, Scialini, Rossoni, Gloria, Salini, Giulia, Savia, Veronica, Lambiase, Antonio, Bordignon, Claudio
Published in Journal of clinical oncology (20.05.2016)
Published in Journal of clinical oncology (20.05.2016)
Get full text
Journal Article